J. Cahiwat

A Small-Molecule Inhibitor of the Wnt Pathway, Lorecivivint (SM04690), as a Potential Disease-Modifying Agent for the Treatment of Degenerative Disc Disease.

J. Hood, Y. Yazici, M. Ibanez, 2020, The spine journal : official journal of the North American Spine Society.

Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment.

B. Melchior, Ch Lai, J. Hood, 2019, Osteoarthritis and cartilage.

A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee.

J. Hood, C. Barroga, M. Ibanez, 2018, Osteoarthritis and cartilage.

The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models.

S. Cha, C. Mak, C. Barroga, 2020, Cancer letters.

A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee.

C. Barroga, M. Ibanez, B. Tam, 2018, Osteoarthritis and cartilage.